Clinical trialNCT03611946CompletedPhase 1Interventional

Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment56Zika Virus

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase 1 double-blind, placebo controlled trial designed to evaluate the safety, reactogenicity, and immunogenicity of a single dose of the live attenuated Zika vaccine rZIKV/D4Δ30-713 in adults with no history of previous flavivirus infection.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Anna Durbin, MD
Center for Immunization Research, Johns Hopkins School of Public Health
Principal Investigator
clinicaltrials.gov ↗
Kristen Pierce, MD
University of Vermont
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Johns Hopkins University, Bloomberg School of Public Health
Baltimore, Maryland, United States
University of Vermont Medical Center (uvmmc), Clinical Research Center
Burlington, Vermont, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Single dose of placebo via subcutaneous injectionSingle dose of rZIKV/D4Δ30-713 via subcutaneous injection

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Jul 2018
Primary completion: 18 Mar 2022
Completion: 18 Mar 2022
Last update posted: 5 Aug 2025
Registered enrollment: 56
Registry id: NCT03611946

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.